Latest news with #ELAN
Yahoo
28-04-2025
- Business
- Yahoo
3 Volatile Stocks with Questionable Fundamentals
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren't prepared. Navigating these stocks isn't easy, which is why StockStory helps you find Comfort In Chaos. That said, here are three volatile stocks best left to the gamblers and some better opportunities instead. Rolling One-Year Beta: 2.58 Started as a Kickstarter campaign, Peloton (NASDAQ: PTON) is a fitness technology company known for its at-home exercise equipment and interactive online workout classes. Why Is PTON Risky? Sluggish trends in its connected fitness subscribers suggest customers aren't adopting its solutions as quickly as the company hoped Suboptimal cost structure is highlighted by its history of operating losses Cash-burning tendencies make us wonder if it can sustainably generate shareholder value Peloton is trading at $6.62 per share, or 9.1x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than PTON. Rolling One-Year Beta: 2.34 Known for its oversized, premium beanbags, Lovesac (NASDAQ:LOVE) is a specialty furniture brand selling modular furniture. Why Does LOVE Worry Us? Sales trends were unexciting over the last two years as its 2.2% annual growth was below the typical consumer discretionary company Capital intensity will likely ramp up in the next year as its free cash flow margin is expected to contract by 1.5 percentage points Shrinking returns on capital suggest that increasing competition is eating into the company's profitability At $21.12 per share, Lovesac trades at 45.9x forward price-to-earnings. To fully understand why you should be careful with LOVE, check out our full research report (it's free). Rolling One-Year Beta: 1.42 Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE:ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries. Why Is ELAN Not Exciting? Weak constant currency growth over the past two years indicates challenges in maintaining its market share Revenue growth over the past five years was nullified by the company's new share issuances as its earnings per share fell by 3.1% annually Negative returns on capital show that some of its growth strategies have backfired Elanco's stock price of $9.50 implies a valuation ratio of 10.7x forward price-to-earnings. If you're considering ELAN for your portfolio, see our FREE research report to learn more. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.
Yahoo
24-04-2025
- Business
- Yahoo
3 Profitable Stocks Walking a Fine Line
While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity". A business making money today isn't necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here are three profitable companies that don't make the cut and some better opportunities instead. Trailing 12-Month GAAP Operating Margin: 5.7% Founded in 2006 in Tel Aviv, (NASDAQ:WIX) offers a free and easy to operate website building platform. Why Does WIX Give Us Pause? Sales trends were unexciting over the last three years as its 11.5% annual growth was below the typical software company Gross margin of 67.9% reflects its relatively high servicing costs At $158.86 per share, Wix trades at 4.8x forward price-to-sales. Dive into our free research report to see why there are better opportunities than WIX. Trailing 12-Month GAAP Operating Margin: 17.5% Originally founded as Coach, Tapestry (NYSE:TPR) is an American fashion conglomerate with a portfolio of luxury brands offering high-quality accessories and fashion products. Why Does TPR Worry Us? Sales trends were unexciting over the last two years as its 1.4% annual growth was below the typical consumer discretionary company Weak constant currency growth over the past two years indicates challenges in maintaining its market share Estimated sales growth of 2.8% for the next 12 months is soft and implies weaker demand Tapestry's stock price of $66.58 implies a valuation ratio of 13.4x forward price-to-earnings. To fully understand why you should be careful with TPR, check out our full research report (it's free). Trailing 12-Month GAAP Operating Margin: 2.3% Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE:ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries. Why Are We Cautious About ELAN? Weak constant currency growth over the past two years indicates challenges in maintaining its market share Issuance of new shares over the last five years caused its earnings per share to fall by 3.1% annually while its revenue grew Negative returns on capital show management lost money while trying to expand the business Elanco is trading at $9.61 per share, or 10.4x forward price-to-earnings. If you're considering ELAN for your portfolio, see our FREE research report to learn more. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
10-04-2025
- Business
- Yahoo
Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement
GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at A replay will also be available on the website shortly following the call. ABOUT ELANCOElanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at Investor Contact: Tiffany Kanaga +1.765.740.0314 Contact: Colleen Parr Dekker +1.317.989.7011 View original content to download multimedia: SOURCE Elanco Animal Health Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle
GREENFIELD, Ind., Feb. 25, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the company's innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle. Medgene reports the vaccine has met all requirements of the U.S. Department of Agriculture's (USDA) platform technology guidelines and is in the final stages of review for conditional license approval. While the poultry industry has developed interventions and processes to reduce the spread or eradicate HPAI, those efforts have continued to be challenging as the current outbreak enters its fourth year. Dairy producers have worked quickly to protect their herds without the same tools and biosecurity options to tackle this devastating disease. The cross-species transmission of the disease into nearly 1,000 dairy herds across the U.S. since March 2024, along with zoonotic transmission to people, shows that more interventions are quickly needed. This virus is prevalent and predicted to persist over time, thus a cattle vaccine will be critical to slow virus spread between birds and cattle. "As egg prices soar and milk production wanes in infected dairies, the need for new solutions to curb disease spread is evident," says Jeff Simmons, President and CEO of Elanco Animal Health. "Elanco is pleased to partner with Medgene to bring customers options to fight this devastating disease and believes this product will become part of a routine vaccination protocol for the U.S. dairy industry. This partnership further strengthens our diverse dairy portfolio and advances our One Health platform of animal health solutions, not only benefitting our dairy customers, but helping curb disease spread for our poultry customers, and working to improve egg prices for consumers." "Medgene has an established reputation of supporting animal owners and their veterinarians with our USDA-licensed platform technology and bioinformatics software to design transformational vaccines. With our critically important H5N1 vaccine for dairy cattle in the final stages of approval, we're excited to partner with Elanco to quickly bring this much needed solution to U.S. dairies," said Mark Luecke, CEO of Medgene. The USDA previously approved Medgene's vaccine platform technology in cattle, allowing the company to accelerate H5N1 vaccine development. Medgene has existing vaccine manufacturing supply ready to deploy with the ability to support the U.S. dairy herd. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product approvals and launches and expectations for contractual relationships. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including whether and when the USDA completes its review, the USDA's determination about any conditional approval, market acceptance of the vaccine, our ability to market and sell the vaccine, competition with other solutions to address highly pathogenic avian influenza and additional factors that could cause actual results to differ materially from forward-looking statements described in the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Investor Contact: Tiffany Kanaga (765) 740-0314 Media Contact: Colleen Dekker (317) 989-7011 View original content to download multimedia: SOURCE Elanco Animal Health
Yahoo
21-02-2025
- Business
- Yahoo
Elanco to Participate in Upcoming Investor Conferences
GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences. On Thursday, February 27, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2025 Animal Health Summit at 12:30 p.m. ET. On Monday, March 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference at 3:10 p.m. ET. On Tuesday, March 11, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference at 9:00 a.m. ET. Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will also be available for a limited time at the conclusion of each event. ABOUT ELANCOElanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at Investor Contact: Tiffany Kanaga (765) 740-0314 Media Contact: Colleen Parr Dekker (317) 989-7011 View original content to download multimedia: SOURCE Elanco Animal Health
